IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: Results of the EORTC Children's Leukemia Group study 58951

Leukemia

Volumn 29, Issue 11, 2015, Pages 2154-2161

  Clappier, E ^a,b   Grardel, N ^c   Bakkus, M ^d   Rapion, J ^e   De Moerloose, B ^f   Kastner, P ^g   Caye, A ^a,b   Vivent, J ^a,b   Costa, V ^h   Ferster, A ⁱ   Lutz, P ^j   Mazingue, F ^k   Millot, F ^l   Plantaz, D ^m   Plat, G ⁿ   Plouvier, E ^o   Poiree M ^p   Sirvent, N ^q   Uyttebroeck, A ^r   Yakouben, K ^a   Girard, S ^s   Dastugue, N ⁿ   Suciu, S ^e   Benoit, Y ^f   Bertrand, Y ^t   Cave H ^a,b   more..

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^e EORTC DATA CENTER   (Belgium)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

^g INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^h PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

ⁱ HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^j HÔPITAL DE HAUTEPIERRE   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l POITIERS UNIVERSITY HOSPITAL   (France)

^m GRENOBLE UNIVERSITY HOSPITAL   (France)

ⁿ CHU PURPAN   (France)

^o UNIVERSITY HOSPITAL OF BESANÇON   (France)

^p UNIVERSITY HOSPITAL OF NICE   (France)

^q MONTPELLIER UNIVERSITY HOSPITAL   (France)

^r UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^s IHOP   (France)

^t UNIVERSITÉ LYON 1   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; DEXAMETHASONE; PREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE; IKAROS TRANSCRIPTION FACTOR; IKZF1 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER PROGNOSIS; CHILD; CHILDHOOD LEUKEMIA; COHORT ANALYSIS; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE; GENE DELETION; GENETIC RISK; HUMAN; IKZF1 GENE; LEUKEMIA RELAPSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; GENETICS; INFANT; MORTALITY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENT DISEASE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE DELETION; HUMANS; IKAROS TRANSCRIPTION FACTOR; INFANT; MALE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECURRENCE;

EID: 84946498651     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.134     Document Type: Article

References (29)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043.
2. Gaynon PS, Angiolillo AL, Carroll WL, Nachman JB, Trigg ME, Sather HN et al. Longterm results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: A Children's Oncology Group Report. Leukemia 2010; 24: 285-297.
3. Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol 2013; 50: 185-196.
4. Roberts KG, Pei D, Campana D, Payne-Turner D, Li Y, Cheng C et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with riskdirected therapy based on the levels of minimal residual disease. J Clin Oncol 2014; 32: 3012-3020.
5. Moorman AV. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev 2012; 26: 123-135.
6. Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol 2013; 162: 606-620.
7. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
8. Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
9. Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010; 24: 1258-1264.
10. Dorge P, Meissner B, Zimmermann M, Moricke A, Schrauder A, Bouquin JP et al. IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol. Haematologica 2013; 98: 428-432.
11. Palmi C, Lana T, Silvestri D, Savino A, Kronnie GT, Conter V et al. Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/ Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". Haematologica 2013; 98: e164-e165.
12. Chen IM, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H et al. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: A Children's Oncology Group study. Blood 2012; 119: 3512-3522.
13. De Moerloose B, Suciu S, Bertrand Y, Mazingue F, Robert A, Uyttebroeck A et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): report of the EORTC randomized phase 3 trial 58951. Blood 2010; 116: 36-44.
14. Domenech C, Suciu S, De Moerloose B, Mazingue F, Plat G, Ferster A et al. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica 2014; 99: 1220-1227.
15. Biondi A, Schrappe M, De Lorenzo P, Castor A, Lucchini G, Gandemer V et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): A randomised, open-label, intergroup study. Lancet Oncol 2012; 13: 936-945.
16. van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 2014; 123: 1691-1698.
17. Guidal C, Vilmer E, Grandchamp B, Cave H. A competitive PCR-based method using TCRD, TCRG and IGH rearrangements for rapid detection of patients with high levels of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2002; 16: 762-764.
18. Clappier E, Auclerc MF, Rapion J, Bakkus M, Caye A, Khemiri A et al. An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions. Leukemia 2014; 28: 70-77.
19. Caye A, Beldjord K, Mass-Malo K, Drunat S, Soulier J, Gandemer V et al. Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica 2013; 98: 597-601.
20. Zaliova M, Zimmermannova O, Dorge P, Eckert C, Moricke A, Zimmermann M et al. ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia. Leukemia 2014; 28: 182-185.
21. Conter V, Valsecchi MG, Silvestri D, Campbell M, Dibar E, Magyarosy E et al. Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: A multicentre randomised trial. Lancet 2007; 369: 123-131.
22. Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011; 25: 254-258.
23. Den Boer ML, van Slegtenhorst M, De Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: A genome-wide classification study. Lancet Oncol 2009; 10: 125-134.
24. Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genomewide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010; 116: 4874-4884.
25. Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 2014; 371: 1005-1015.
26. Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22: 153-166.
27. Izraeli S. Beyond Philadelphia: 'Ph-like' B cell precursor acute lymphoblastic leukemias-diagnostic challenges and therapeutic promises. Curr Opin Hematol 2014; 21: 289-296.
28. van der Veer A, Waanders E, Pieters R, Willemse ME, Van Reijmersdal SV, Russell LJ et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. Blood 2013; 122: 2622-2629.
29. Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J et al. RAGmediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet 2014; 46: 116-125.